Carperitide

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 17 September 2026

Carperitide is a real natriuretic peptide drug for acute heart failure — approved in Japan in 1995 and still widely used there, but never approved in the US, and notably approved decades ago without the kind of large randomized mortality trial modern regulators would require, with more recent real-world data actively raising a mortality concern.

In brief

Should you care? Relevant if you're researching international heart-failure treatment approaches, or comparing natriuretic-peptide drugs across the three covered on this site.

The short version

Approved in Japan in 1995, and still the dominant heart-failure injectable there — but never FDA-approved.
No large placebo-controlled trial has ever confirmed it improves outcomes — its approval predates that evidentiary bar.
A 2015 propensity-matched study found it associated with increased in-hospital mortality (odds ratio 2.13) — a real, concerning signal from real-world data, not a confirmed causal finding but not nothing either.

A natriuretic peptide, Japan-only

Carperitide is recombinant human alpha-type atrial natriuretic peptide (ANP) — the same natriuretic-peptide family as ularitide (urodilatin) and nesiritide (BNP analog) elsewhere on this site, causing vasodilation, natriuresis, and suppression of the renin-angiotensin system. Japan's health ministry approved it in 1995 for acute heart failure, and it became — and remains — the dominant injectable heart-failure drug there. It has never been approved by the FDA, and no sponsor currently has an active US application for it.

An evidence base thinner than a modern approval would require

Here's the important honesty point: carperitide's 1995 approval predates the kind of large, placebo-controlled, mortality/morbidity outcome trial that would be expected of a new heart-failure drug today — no such trial has ever been run to confirm it actually improves symptoms, hospitalization, or survival. More concerning, a 2015 propensity-score-matched analysis (Matsue et al., J Card Fail 2015, PMID 25999241) found carperitide use associated with increased in-hospital mortality (odds ratio 2.13, 95% CI 1.17-3.85), with a larger effect in elderly patients specifically. A more recent randomized trial, LASCAR-AHF (2024), found low-dose carperitide did not reduce long-term mortality or hospitalization compared to standard treatment. None of this proves the drug causes harm — the 2015 finding is observational, not a randomized causal result — but it's a real, documented concern sitting on top of an approval that was never put through the trial modern regulators would demand.

Why it never reached the US

Astellas held North American development rights at one point and terminated the licensing agreement, citing reassessed competitive circumstances and market potential — a commercial decision, not a rejected FDA application or a safety finding against it. Carperitide simply never went through the US regulatory process at all, rather than trying and failing.

References

Matsue Y, Kagiyama N, Yamaguchi T, et al., "Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis," J Card Fail 2015;21(11):859-864, PMID 25999241.
Japanese Ministry of Health, Labour and Welfare approval of carperitide, 1995 (Japan only; no FDA application on file).